Percutaneous closure of restrictive‐type perimembranous ventricular septal defect using the new KONAR multifunctional occluder: Midterm outcomes of the first middle‐eastern experience

Objectives To evaluate the safety, efficiency, and midterm outcomes of transcatheter perimembranous ventricular septal defect (pmVSD) closure using the new KONAR‐MF™ VSD occluder. Background Off‐label percutaneous pmVSD closure is a well‐established procedure with promising results. Yet, interventionists are still searching for the ideal device. Methods Between June 2018 and March 2019, 20 patients with hemodynamically significant but restrictive‐type pmVSD underwent an attempted transcatheter closure using the new KONAR‐MF™. All implantations were performed retrogradely under general anesthesia, transoesophageal echocardiography, and fluoroscopic guidance. Prospective follow‐up using transthoracic echocardiography and electrocardiogram was done until August 2019. Results The median age was 6.4 years (8 months to 43.4 years), and the median body weight was 17.3 (9–74) kg. The mean defect size on the left ventricular aspect was 11.7 ± 2.8 mm. All devices were successfully and rapidly implanted. One device embolized in the pulmonary artery, 24 hr after implantation and was percutaneously retrieved with no complication. Over a mean follow‐up period of 8.2 ± 3.0 months, complete closure was achieved in 84.2% of patients. One new onset of mild aortic regurgitation was detected before discharge and remained stable. Tricuspid valve regurgitation, complete heart block, major complication, and death were not observed. Conclusions Transcatheter pmVSD closure using the KONAR‐MF™ can be successfully performed in adult and pediatric patients. It is a safe and promising device, designed to provide high conformability to septal defects with a lower risk of heart block. Retrograde implantation allows procedural flexibility, efficient deliverability, and control of valvular interferences.